Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.
Carpentier
Alexandre
A
Department of Neurosurgery, Hôpital Lariboisiére, Paris, France. antoine.carpentier@avc.aphp.fr
Metellus
Philippe
P
Ursu
Renata
R
Zohar
Sarah
S
Lafitte
Francois
F
Barrié
Maryline
M
Meng
Yuxia
Y
Richard
Margaretha
M
Parizot
Christophe
C
Laigle-Donadey
Florence
F
Gorochov
Guy
G
Psimaras
Dimitri
D
Sanson
Marc
M
Tibi
Annick
A
Chinot
Olivier
O
Carpentier
Antoine F
AF
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D009838:Oligodeoxyribonucleotides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015996:Survival Rate; D014018:Tissue Distribution; D016896:Treatment Outcome
C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides